NCT00165451已完成2 期
Anti-Angiogenic Chemotherapy: A Phase II Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- To evaluate the feasibility of administering thalidomide, celecoxib, etoposide and cyclophosphamide for recurrent and poor prognosis tumors.
研究概览
简要总结
This study will use a combination of four oral drugs (thalidomide, cyclophosphamide, etoposide and celecoxib) to treat patients with relapsed or progressive cancer. These drugs are expected to target the blood vessels that supply the tumors with what they need to grow.
详细描述
- Thalidomide will be given orally every evening and the daily dose will escalate until the patient reaches a dose on which they are comfortable and will given continuously for one year.
- Celecoxib will be given orally twice a day and escalated as tolerated for one year.
- Etoposide will be given orally once a day for 21 consecutive days. This medication will alternate with oral cyclophosphamide and will continue for one year.
- Cyclophosphamide will be given orally once a day for 21 consecutive days and as stated above will alternate with etoposide for one year.
- During the treatment, blood tests will be performed every three weeks except during the first 3 week cycle in which testing is performed every 2 weeks. Appropriate imaging studies will be performed every 9 weeks.
- The duration of treatment is one year unless the side effects are too harmful or the tumor grows. Treatment may be continued past one year if the drugs are well tolerated and disease progression has not occured.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- — 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with relapsed or progressive poor prognosis tumors for which no curative therapy exists.
- •Histologic confirmation of disease at diagnosis or relapse.
- •Brain stem glioma patients who have progressed after radiation therapy do not require histologic confirmation. Duration of symptoms at the time of diagnosis must be less than 3 months and should consist of cranial nerve deficits and/or ataxia and/or long tract signs.
- •Prior radiation therapy and/or chemotherapy are permitted.
- •Karnofsky Performance Status >
- •For infants, the Lansky play scale >50% can be substituted.
- •Life expectancy > 2 months.
- •No active uncontrolled cardiac, hepatic, renal, or psychiatric disease defined as ≥ grade 3 based on the common toxicity criteria.
- •No known allergies to sulfonamides
- •Adequate renal function: Serum Creatinine < 1.5 mg/dl or creatinine clearance or GFR > 70 ml/min.
- •Adequate hepatic function: Total Bilirubin < 1.5 mg/dl; SGOT, SGPT, Alk Phos < 3x normal.(SGOT can be < 4x normal for patients on Zantac).
- •Adequate bone marrow reserve: Hgb > 9.0 g/dl, Platelets > 75,000/mm3 (transfusion independent),WBC > 2000/mm3 and ANC > 1000/mm
- •Patients receiving steroids and/or anti-seizure medications are eligible for this study.
排除标准
- •Patients must not be pregnant or nursing, and all patients of child bearing age (both male and female) must be willing to practice birth control during and for 2 months after treatment with thalidomide. If the patient is unable to use oral contraceptives for medical reasons, 2 different barrier methods may be used if approved by the treating physician.
- •No concurrent use of other investigational agents.
- •Patients that have received more than 2 months of oral therapy with any of the agents used in this study will be ineligible. Standard administration of IV etoposide and cyclophosphamide, usually administered in 3-week cycles is permitted.
结局指标
主要结局
To evaluate the feasibility of administering thalidomide, celecoxib, etoposide and cyclophosphamide for recurrent and poor prognosis tumors.
时间窗: 6 months
次要结局
- To obtain preliminary evidence of biologic activity of these four orally administered(6 months)
- to evaluate and document side effects from chronic administration of these four drugs at the doses prescribed in this protocol(6 months)
- to evaluate different radiographic techniques as markers of tumor response.(6 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive CancerCentral Nervous System Tumor, PediatricUnspecified Childhood Solid Tumor, Protocol SpecificLymphomaSarcomaLeukemiaNeuroblastomaNCT00357500Dana-Farber Cancer Institute101
进行中（未招募）
2 期
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian CancerOvarian NeoplasmsFallopian Tube NeoplasmsNeoplasms by SiteGenital Neoplasms, FemaleNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeCarcinoma, Ovarian EpithelialOvarian DiseasesGenital Diseases, FemaleEndocrine System DiseasesCarcinomaAnlotinibAngiogenesisAntineoplastic AgentsTyrosine Kinase InhibitorNCT04807166Wenjun Cheng56
进行中（未招募）
2 期
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeNCT05453500University of Washington32
已完成
3 期
D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple MyelomaMultiple MyelomaNCT00083876University of Arkansas500
已完成
2 期
Phase II Study of RT-PEPC in Relapsed Mantle Cell LymphomaNon-Hodgkin's LymphomaNCT00151281Weill Medical College of Cornell University25